Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BRETEC.HE
- Price
- 0.51
- Stock movement down
- -0.03 (-6.03%)
- Company name
- Bioretec Oy
- Exchange
- (HE ,
- Currency
- EUR )
- Sector
- Healthcare >Medical Devices
- Market cap
- 14.87M
- Ent value
- -
- Price/Sales
- 2.03
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -79.53%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2026-01-19
DIVIDENDS
BRETEC.HE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.03 |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 30.79M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 7.32M |
| Gross profit (TTM) | 4.24M |
| Operating income (TTM) | -7.32M |
| Net income (TTM) | -8.70M |
| EPS (TTM) | - |
| EPS (1y forward) | -0.32 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 57.88% |
| Operating margin (TTM) | -99.99% |
| Profit margin (TTM) | -118.84% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 0.00 |
| Net receivables | 0.00 |
| Total current assets | 15.89M |
| Goodwill | 0.00 |
| Intangible assets | 760.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 17.94M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 3.26M |
| Total liabilities | 3.50M |
| Shareholder's equity | 14.44M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -11.23M |
| Capital expenditures (TTM) | 1.41M |
| Free cash flow (TTM) | -12.63M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.51 |
| Daily high | 0.51 |
| Daily low | 0.47 |
| Daily Volume | 226K |
| All-time high | 3.26 |
| 1y analyst estimate | 1.20 |
| Beta | - |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| BRETEC.HE | S&P500 | |
| Current price drop from All-time high | -84.23% | -0.50% |
| Highest price drop | -85.18% | -19.00% |
| Date of highest drop | 19 Jan 2026 | 8 Apr 2025 |
| Avg drop from high | -46.09% | -2.50% |
| Avg time to new high | - | 6 days |
| Max time to new high | 316 days | 89 days |
COMPANY DETAILS
Marketcap
14.87M
Marketcap category
Small-cap
Description
Bioretec Oy, a medical device company, develops, manufactures, and markets bioresorbable orthopedic implants for the repair of bone and soft tissue injuries in children and adults worldwide. The company offers Activa IM-Nail, a bioabsorbable option for pediatric forearm intramedullary nailing; ActivaNail, an implant that is be used in upper or lower limbs to ensure successful bone regeneration; ActivaPin, a bioabsorbable implant for upper and lower limb fractures; and ActivaScrew, an absorbable surgical implant that is used in fracture treatment, osteotomy, arthrodesis, and bone graft surgery. It also provides ActivaScrew Cannulated that offers a range of fully threaded and partially threaded cannulated screws for fixation of fractures and osteotomies; ActivaScrew Interference, a tool for multiple uses regarding bone fractures, osteotomies, arthrodesesm, and bone grafts; ActivaScrew Interference TCP, a biocomposite interference screw; and RemeOs Screw, a magnesium screw implants. The company was formerly known as BCI Bioabsorbable Concepts Oy. The company was incorporated in 1998 and is headquartered in Tampere, Finland.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Finland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Bioretec Ltd, a pioneer in absorbable orthopedic implants, was granted Transitional Pass-Through Payment (TPT) status by the U.S. Centers for Medicare & Medicaid Services (CMS) for its RemeOs™ Trauma ...
January 16, 2026
Bioretec Ltd., a pioneer in absorbable orthopedic implants appoints Tuukka Paavola (M.Sc. Industrial Engineering, CFA) as Chief Financial Officer, effective 20 January 2025. In this role, Paavola will...
January 15, 2026
In 2025, Bioretec will publish the following financial reports:
December 22, 2025
As announced in September, Bioretec Ltd ("Bioretec" or the "Company") has assessed its overall commercialization strategy, pipeline, and options to accelerate growth. Bioretec's Board of Directors has...
December 16, 2025
Bioretec Oy ("Bioretec" or the "Company"), a pioneer in biodegradable orthopedic implants, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its magne...
December 14, 2025
On November 12, 2025, Bioretec announced the start of statutory change negotiations under the Finnish Act on Co-operation within Undertakings, concerning the company's production and marketing operati...
December 4, 2025
This announcement summarizes Bioretec Ltd's business review for January–September 2025. The complete business review is attached to this release as a PDF file and available on the company's website at...
November 13, 2025
Bioretec Ltd is initiating change negotiations in accordance with the Finnish Act on Co-operation within Undertakings. The aim of the negotiations is to streamline and reorganize operations in order t...
November 12, 2025
Bioretec announced on 27 October 2025 that it will adjust and restate its previously reported figures for H1/2025.
October 31, 2025
On 22 November 2024, Bioretec Ltd ("Bioretec" or the "Company"), announced through a press release a new sales and distribution agreement with Tri-State Biologics ("TSB"), enabling the sale and distri...
October 27, 2025
Next page